{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:47:35Z","timestamp":1789026455174,"version":"build-2803163510"},"reference-count":64,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The aim of personalized cancer vaccines is to elicit potent and tumor-specific immune responses against neoantigens specific to each patient and to establish durable immunity, while minimizing the adverse events. Over recent years, there has been a renewed interest in personalized cancer vaccines, primarily due to the advancement of innovative technologies for the identification of neoantigens and novel vaccine delivery platforms. Here, we review the emerging field of personalized cancer vaccination, with a focus on the use of viral vectors as a vaccine platform. The recent advancements in viral vector technology have led to the development of efficient production processes, positioning personalized viral vaccines as one of the preferred technologies. Many clinical trials have shown the feasibility, safety, immunogenicity and, more recently, preliminary evidence of the anti-tumor activity of personalized vaccination, fostering active research in the field, including further clinical trials for different tumor types and in different clinical settings.<\/jats:p>","DOI":"10.3390\/ijms242316591","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T03:54:37Z","timestamp":1700625277000},"page":"16591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-3355","authenticated-orcid":false,"given":"Laura","family":"Secl\u00ec","sequence":"first","affiliation":[{"name":"Nouscom, Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0502-1962","authenticated-orcid":false,"given":"Guido","family":"Leoni","sequence":"additional","affiliation":[{"name":"Nouscom, Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Ruzza","sequence":"additional","affiliation":[{"name":"Nouscom, Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Siani","sequence":"additional","affiliation":[{"name":"Nouscom, Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Cotugno","sequence":"additional","affiliation":[{"name":"Nouscom, Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Scarselli","sequence":"additional","affiliation":[{"name":"Nouscom, Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-6269","authenticated-orcid":false,"given":"Anna Morena","family":"D\u2019Alise","sequence":"additional","affiliation":[{"name":"Nouscom, Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nri.2017.140","article-title":"The Dawn of Vaccines for Cancer Prevention","volume":"18","author":"Finn","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities","volume":"29","author":"Shemesh","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic Cancer Vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.smim.2018.04.001","article-title":"Correlates of Immune and Clinical Activity of Novel Cancer Vaccines","volume":"39","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00281-018-0691-z","article-title":"Therapeutic Cancer Vaccine: Building the Future from Lessons of the Past","volume":"41","author":"Tran","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized Vaccines for Cancer Immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s43018-023-00588-x","article-title":"The Landscape of T Cell Antigens for Cancer Immunotherapy","volume":"4","author":"Peri","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Buonaguro, L., and Tagliamonte, M. (2020). Selecting Target Antigens for Cancer Vaccine Development. Vaccines, 8.","DOI":"10.3390\/vaccines8040615"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective Identification of Neoantigen-Specific Lymphocytes in the Peripheral Blood of Melanoma Patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","article-title":"Towards New Horizons: Characterization, Classification and Implications of the Tumour Antigenic Repertoire","volume":"17","author":"Haen","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1084\/jem.20172188","article-title":"Shared Cancer Neoantigens: Making Private Matters Public","volume":"215","author":"Klebanoff","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer Immunology. Mutational Landscape Determines Sensitivity to Pd-1 Blockade in Non-Small Cell Lung Cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal Neoantigens Elicit T Cell Immunoreactivity and Sensitivity to Immune Checkpoint Blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41467-019-10594-2","article-title":"Adenoviral Vaccine Targeting Multiple Neoantigens as Strategy to Eradicate Large Tumors Combined with Checkpoint Blockade","volume":"10","author":"Leoni","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.it.2018.04.005","article-title":"Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different","volume":"39","author":"Lee","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer Neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fimmu.2020.00027","article-title":"Computational Prediction and Validation of Tumor-Associated Neoantigens","volume":"11","author":"Roudko","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the Development of Personalized Neoantigen-Based Therapeutic Cancer Vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of Neoantigens for Individualized Therapeutic Cancer Vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"979928","DOI":"10.3389\/fgene.2022.979928","article-title":"Towards an Accurate and Robust Analysis Pipeline for Somatic Mutation Calling","volume":"13","author":"Jin","year":"2022","journal-title":"Front. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational Landscape and Significance across 12 Major Cancer Types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.annonc.2020.05.008","article-title":"Neoantigen Prediction and Computational Perspectives Towards Clinical Benefit: Recommendations from the Esmo Precision Medicine Working Group","volume":"31","author":"Vazquez","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.4049\/jimmunol.1700744","article-title":"Emerging Concepts in Tcr Specificity: Rationalizing and (Maybe) Predicting Outcomes","volume":"199","author":"Singh","year":"2017","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S2213-8587(15)00494-5","article-title":"Insulin Patents and Market Exclusivities: Unresolved Issues\u2014Authors\u2019 Reply","volume":"4","author":"Luo","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1093\/bioinformatics\/btx377","article-title":"Timiner: Ngs Data Mining Pipeline for Cancer Immunology and Immunotherapy","volume":"33","author":"Tappeiner","year":"2017","journal-title":"Bioinformatics"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liu, C., Zhang, Y., Jian, X., Tan, X., Lu, M., Ouyang, J., Liu, Z., Li, Y., Xu, L., and Chen, L. (2022). Progeo-Neo V2.0: A One-Stop Software for Neoantigen Prediction and Filtering Based on the Proteogenomics Strategy. Genes, 13.","DOI":"10.3390\/genes13050783"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4049\/jimmunol.1600582","article-title":"Pan-Specific Prediction of Peptide-Mhc Class I Complex Stability, a Correlate of T Cell Immunogenicity","volume":"197","author":"Rasmussen","year":"2016","journal-title":"J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rubinsteyn, A., Hodes, I., Kodysh, J., and Hammerbacher, J. (2018). Vaxrank: A Computational Tool for Designing Personalized Cancer Vaccines. Biorxiv.","DOI":"10.1101\/142919"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Leoni, G., D\u2019Alise, A.M., Tucci, F.G., Micarelli, E., Garzia, I., De Lucia, M., Langone, F., Nocchi, L., Cotugno, G., and Bartolomeo, R. (2021). Venus, a Novel Selection Approach to Improve the Accuracy of Neoantigens\u2019 Prediction. Vaccines, 9.","DOI":"10.3390\/vaccines9080880"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen Quality Predicts Immunoediting in Survivors of Pancreatic Cancer","volume":"606","author":"Luksza","year":"2022","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jnci\/87.13.982","article-title":"Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes from Patients Immunized with Recombinant Vaccinia-Cea Vaccine","volume":"87","author":"Tsang","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_34","first-page":"676","article-title":"Induction of Protective Host Immunity to Carcinoembryonic Antigen (Cea), a Self-Antigen in Cea Transgenic Mice, by Immunizing with a Recombinant Vaccinia-Cea Virus","volume":"59","author":"Kass","year":"1999","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/jnci\/84.14.1084","article-title":"Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine","volume":"84","author":"Kantor","year":"1992","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal Immunity and Vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.virol.2008.04.023","article-title":"Derivation of a Triple Mosaic Adenovirus Based on Modification of the Minor Capsid Protein Ix","volume":"377","author":"Tang","year":"2008","journal-title":"Virology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","article-title":"New Viral Vectors for Infectious Diseases and Cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A Review of 65 Years of Human Adenovirus Seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, Heterologous Chimpanzee Adenovirus and Self-Amplifying Mrna Neoantigen Vaccine for Advanced Metastatic Solid Tumors: Phase 1 Trial Interim Results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"LB196","DOI":"10.1158\/1538-7445.AM2023-LB196","article-title":"Abstract Lb196: Nous-Pev, a Personalized Cancer Immunotherapy Targeting Neoantigens, Induces Long Lasting, Tumor Infiltrating Memory T Cells","volume":"83","author":"Bechter","year":"2023","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"eabo7604","DOI":"10.1126\/scitranslmed.abo7604","article-title":"Adenoviral-Based Vaccine Promotes Neoantigen-Specific Cd8(+) T Cell Stemness and Tumor Rejection","volume":"14","author":"Brasu","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host Range and Cytopathogenicity of the Highly Attenuated Mva Strain of Vaccinia Virus: Propagation and Generation of Recombinant Viruses in a Nonhuman Mammalian Cell Line","volume":"238","author":"Carroll","year":"1997","journal-title":"Virology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia Vectors as Candidate Vaccines: The Development of Modified Vaccinia Virus Ankara for Antigen Delivery","volume":"3","author":"Sutter","year":"2003","journal-title":"Curr. Drug. Targets Infect. Disord."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/infdis\/jiq105","article-title":"Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing Hiv-1 Virus-Like Particles","volume":"203","author":"Goepfert","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/421266","article-title":"Modified Vaccinia Ankara: Potential as an Alternative Smallpox Vaccine","volume":"38","author":"McCurdy","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A Human Vaccine Strategy Based on Chimpanzee Adenoviral and Mva Vectors That Primes, Boosts, and Sustains Functional Hcv-Specific T Cell Memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and Immunogenicity of Imvamune, a Promising Candidate as a Third Generation Smallpox Vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"113927","DOI":"10.1016\/j.addr.2021.113927","article-title":"Enhancing Therapeutic Performance of Personalized Cancer Vaccine Via Delivery Vectors","volume":"177","author":"Ye","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e000928","DOI":"10.1136\/jitc-2020-000928","article-title":"Safety and Immunogenicity of Novel 5t4 Viral Vectored Vaccination Regimens in Early Stage Prostate Cancer: A Phase I Clinical Trial","volume":"8","author":"Cappuccini","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1158\/0008-5472.CAN-20-1072","article-title":"A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability","volume":"80","author":"Leoni","year":"2020","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Li, X., Le, Y., Zhang, Z., Nian, X., Liu, B., and Yang, X. (2023). Viral Vector-Based Gene Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097736"},{"key":"ref_53","unstructured":"EMA (2017). Guidelines on Good Manufacturing Practice Specific to Advanced Therapy Medicinal Products, European Medicines Agency."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"103773","DOI":"10.1016\/j.drudis.2023.103773","article-title":"Personalized Neoantigen Cancer Vaccines: An Analysis of the Clinical and Commercial Potential of Ongoing Development Programs","volume":"28","author":"Perrinjaquet","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.tibtech.2023.04.006","article-title":"Manufacturing Innovation to Drive Down Cell Therapy Costs","volume":"41","author":"Khang","year":"2023","journal-title":"Trends Biotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-19-2881","article-title":"A Pan-Cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors","volume":"26","author":"Fang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"691605","DOI":"10.3389\/fimmu.2021.691605","article-title":"A Neoantigen-Based Peptide Vaccine for Patients with Advanced Pancreatic Cancer Refractory to Standard Treatment","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1000681","DOI":"10.3389\/fimmu.2022.1000681","article-title":"Combination Treatment of Radiofrequency Ablation and Peptide Neoantigen Vaccination: Promising Modality for Future Cancer Immunotherapy","volume":"13","author":"Shou","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized Rna Neoantigen Vaccines Stimulate T Cells in Pancreatic Cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2019.37.15_suppl.2523","article-title":"A Phase I Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of Mrna-4157 Alone in Patients with Resected Solid Tumors and in Combination with Pembrolizumab in Patients with Unresectable Solid Tumors","volume":"37","author":"Burris","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"LBA9515","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9515","article-title":"Minimal Residual Disease by Circulating Tumor DNA as a Biomarker of Recurrence Free Survival in Resected High-Risk Melanoma Patients Treated with Mrna-4157\/V940, a Personalized Cancer Vaccine, and Pembrolizumab","volume":"41","author":"Carlino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"LBA9503","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9503","article-title":"Distant Metastasis-Free Survival Results from the Randomized, Phase 2 Mrna-4157-P201\/Keynote-942 Trial","volume":"41","author":"Khattak","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/d41573-023-00118-5","article-title":"Personalized Cancer Vaccines Pass First Major Clinical Test","volume":"22","author":"Dolgin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"Il-1 and Il-1ra Are Key Regulators of the Inflammatory Response to Rna Vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:26:49Z","timestamp":1760131609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":64,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijms242316591"],"URL":"https:\/\/doi.org\/10.3390\/ijms242316591","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]}}}